The first quarter of the fiscal year 2023/2024 has been good for VibroSense and the company continues the positive development with Diabetes Foot Screening . The company has delivered instruments to new customers and the positive sales trend continues for the fifth quarter in a row!

Marketing and sales activities
During the most recent period, VibroSense activities have continued to focus on Sweden, China and Germany. As previously announced, the company will participate in a number of international congresses during the autumn, with the opportunity to interact with both potential customers, researchers and possibly also with potential distributors. VibroSense is participating as an exhibitor at the EASD congress in Hamburg on October 2-6. We look forward to further presenting our product on the international stage. Partly for German actors but also for potential partners and customers from other markets.

The work to apply for registration and approval regarding the sale of our product on the Chinese market is progressing at a good pace. VibroSense collaborates here with its partner and distributor in China, UMCARE who handles the entire work of applying for a regulatory approval in China.

In the company's year-end report, it was announced that the tests of the product, which precede an application for registration, are in their final stages. These tests are now completed and approved and we await a final report from the contracted test institute in Shanghai. UMCARE had expected to receive this report by the end of September, but the testing institute has announced that this will take another few weeks.

Once the test report is received, UMCARE will assemble and submit a complete application for registration of the VibroSense Meter® II to the NMPA in China. As the process is dependent on external actors, it is difficult to predict an exact date for the submission of the application to NMPA. According to our latest estimate, this will take place at the end of October 2023, after which the NMPA is expected to reply within 2-3 months.

VibroSense will notify the market via press release as soon as the application is submitted to the Chinese authority NMPA.

Overall, the first quarter has been very promising and our expectations that 2023/2024 could be a breakthrough year for VibroSense remain.

Contact
Hans Wallin, CEO VibroSense Dynamics AB
Phone: +46 40 88 026
Email: info@vibrosense.com
www.vibrosense.se

"The new Gold Standard for reliable detection of nerve damage"

About VibroSense Dynamics AB ( publ )
VibroSense Dynamics AB ( publ ) develops and sells medical technology products and services for diagnostic support for nerve damage in the hands and feet. The method involves measuring and quantifying the ability to feel vibrations at several frequencies.

The company's customers are diabetes clinics, occupational health care, hospitals, health centers and researchers. Our vision is that the company's products should be a standard instrument in all neurological examinations to detect early signs of changes in sensation so that patients and their caregivers can implement preventive measures that prevent, reduce or delay the onset of nerve damage in the hands and feet.